We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+48.36%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$184M
AUM Growth
–
Cap. Flow
+$164M
Cap. Flow %
89.08%
Top 10 Hldgs %
54.84%
Holding
28
New
28
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$14M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$12.3M
3
CBAY
Cymabay Therapeutics
CBAY
+$11.2M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$10.7M
5
KRON
Kronos Bio
KRON
+$9.38M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 91.66%
2 Financials 1.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCCC icon
1
C4 Therapeutics
CCCC
$376M
$15.9M 8.67%
+481,094
New +$14M
TRIL
2
DELISTED
Trillium Therapeutics Inc.
TRIL
$12.5M 6.82%
+852,871
New +$12.3M
CNST
3
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$12.2M 6.63%
+423,708
New +$10.7M
FPRX
4
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$9.05M 4.92%
+532,000
New +$6.67M
KRON
5
DELISTED
Kronos Bio
KRON
$8.93M 4.85%
+298,839
New +$9.38M
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.8M 4.79%
+1,274,261
New +$8.15M
ACRS icon
7
Aclaris Therapeutics
ACRS
$730M
$8.65M 4.7%
+1,336,275
New +$5.64M
COGT icon
8
Cogent Biosciences
COGT
$6.79B
$8.54M 4.64%
+760,025
New +$8.35M
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$8.53M 4.64%
+1,486,107
New +$11.2M
PMVP icon
10
PMV Pharmaceuticals
PMVP
$66.1M
$7.69M 4.18%
+125,000
New +$4.9M
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$1.84B
$7.35M 3.99%
+330,315
New +$6.85M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.32B
$7.19M 3.91%
+467,368
New +$5.47M
PTGX icon
13
Protagonist Therapeutics
PTGX
$8.75B
$7.01M 3.81%
+347,500
New +$7.48M
MREO
14
Mereo BioPharma
MREO
$45.9M
$6.64M 3.61%
+1,854,278
New +$4.64M
CLDX icon
15
Celldex Therapeutics
CLDX
$2.77B
$6.25M 3.4%
+356,431
New +$6.41M
VTGN icon
16
VistaGen Therapeutics
VTGN
$9.29M
$6.11M 3.32%
+105,000
New +$2.68M
RLMD icon
17
Relmada Therapeutics
RLMD
$544M
$5.73M 3.11%
+178,565
New +$6.14M
SPRY icon
18
ARS Pharmaceuticals
SPRY
$590M
$4.5M 2.45%
+97,143
New +$3.24M
KURA icon
19
Kura Oncology
KURA
$922M
$4.36M 2.37%
+133,503
New +$4.69M
SURF
20
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$4.32M 2.35%
+467,796
New +$4.07M
GNCA
21
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.27M 2.32%
+1,765,901
New +$4.02M
MRSN
22
DELISTED
Mersana Therapeutics
MRSN
$4.23M 2.3%
+6,353
New +$3.53M
IMVT icon
23
Immunovant
IMVT
$8.09B
$3.87M 2.1%
+83,782
New +$3.87M
IVA
24
Inventiva
IVA
$1.05B
$3.35M 1.82%
+231,000
New +$2.99M
BLSA
25
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.79M 1.51%
+250,000
New +$2.68M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Commodore Capital, which disclosed 28 positions worth $184M. Its ten largest holdings account for 55% of the portfolio.

Its largest position is C4 Therapeutics: 481,094 shares worth $15.9M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, followed by Financials.

  • Commodore Capital's largest Q4 2020 buy was C4 Therapeutics: 481,094 shares worth $15.9M.
  • Commodore Capital's ten largest holdings make up 55% of its $184M portfolio in Q4 2020.
  • Commodore Capital disclosed 28 positions in Q4 2020, its first 13F filing on record.

Based on Commodore Capital's 13F filing for Q4 2020, filed 16 Feb 2021.